Zvi is a myeloma patient and an active member of the organisation AMEN (Israel). He has graduated in Computer Science from the Technion, Israel Institute of Technology and has a master’s in MBA with distinction from Derby University. He is a Software engineer with 25 years of experience in the fields of development, marketing, and program management in various hi-tech companies. For the last ten years, Zvi has worked for Intel Israel. He aims to improve early diagnosis of myeloma. In addition, he is willing to strengthen patient organisations across Europe by sharing knowledge and information. Zvi completed the MPE Advocate Development Program (ADP) in 2021.
The National Institute for Health and Care Excellence (NICE) approves the use of elranatamab as a fourth-line treatment for myeloma in England and Wales
On the 21st of June NICE, the United Kingdom’s public body for medicine appraisals, approved the use of the UK’s first bispecific drug for myeloma, elranatamab. Evidence from an…